Listed by the USPTO as COFFA, SERGIO
Tech Center 1600 • Art Units: 1654 1658 1671 1675 1676
This examiner grants 61% of resolved cases
COFFA, SERGIO is assigned to tech center 1600 and art unit 1654. The record includes 760 resolved cases, with an allowance rate of 61.2%. The median time to allowance is 1072 days, giving applicants a substantial historical reference for prosecution duration.
The interview lift is 32.3%, indicating a positive association between interviews and allowance outcomes. The listed companies are Axoltis Pharma, Novo Nordisk A/S, and Takeda Pharmaceutical Company Limited. The recurring firms are FOLEY & LARDNER LLP, LICATA & TYRRELL P.C., and Muncy, Geissler, Olds & Lowe, P.C. The large record supports using the figures for planning context, while application-specific claim and prior-art analysis remains essential.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19463848 | SEMAGLUTIDE IN MEDICAL THERAPY | Final Rejection | Novo Nordisk A/S |
| 18686954 | FUNCTIONALIZED, DECELLULARIZED CORNEAL EXTRACELLULAR MATRIX HYDROGELS FOR OCULAR TISSUE TREATMENT | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18316988 | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18833263 | DISRUPTION OF SONIC HEDGEHOG-SURF4 INTERACTION FOR CANCER TREATMENT | Non-Final OA | The Hong Kong University of Science and Technology |
| 18257483 | COMPOSITIONS AND METHODS FOR MODULATING MYC EXPRESSION | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 18553437 | ANGIOGENESIS INHIBITING PEPTIDE AND USE THEREOF | Non-Final OA | SEOUL NATIONAL UNIVERSITY HOSPITAL |
| 18571666 | A NOVEL COMPOUND ACTING AGAINST A SELECT GROUP OF BACTERIA | Non-Final OA | Northeastern University |
| 18580752 | PEPTIDE, COMPOSITION FOR RECOVERING RARE EARTH ELEMENTS COMPRISING SAME, AND RECOVERY METHOD | Non-Final OA | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17767734 | IFIT Polypeptides and Uses for Treating Tuberculosis Infection | Non-Final OA | Stellenbosch University |
| 17518047 | METHOD FOR TREATING OPIOID USE DISORDER | Final Rejection | The United States Government as represented by the Department of Veterans Affairs |
| 17267652 | COMPOUNDS USEFUL FOR THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS AND/OR MUCOUS MEMBRANES | Final Rejection | LUBRIZOL ADVANCED MATERIALS, INC. |
| 18262113 | USE OF LINK-TSG6 FOR THE TREATMENT OF OSTEOARTHRITIC PAIN | Non-Final OA | The University of Manchester |
| 16610826 | STABLE INSULIN FORMULATIONS | Final Rejection | Arecor Limited |
| 18561469 | KIDNEY ACTIVE FUSION PROTEINS AND METHODS OF TREATMENT USING THE SAME | Non-Final OA | Alexion Pharmaceuticals, Inc. |
| 18280632 | Methods and Compositions for Treatment of Disease | Final Rejection | Coya Therapeutics, Inc. |
| 18577588 | IL1RA DERIVED PEPTIDES FOR TREATMENT OF DIABETIC NEPHROPATHY | Non-Final OA | SERODUS APS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy61.2% of resolved applications examined by Sergio Coffa were allowed (760 resolved cases), compared with 48.2% across Art Unit 1654 over the last five years.
This examiner's interview lift is +32.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Sergio Coffa took 1,072 days on average from filing to allowance.
Sergio Coffa examines applications in Art Unit 1654 in Tech Center 1600 (Biotechnology & Pharmaceuticals).